Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2022-09-21 Regulatory Filings
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Resignation of Internal Auditor
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the resignation of the internal auditor of the company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information. The content is an announcement of a change in a key company function (internal audit), which falls under management or corporate governance changes. The document is brief (1322 characters) and does not contain financial data or detailed reports. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories like Board/Management Information (MANG) which typically involves board or senior management changes, not internal audit function changes.
2022-09-21 English
Resignation
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the resignation of the internal auditor of the company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a change in a key company function (internal audit), but it does not contain any financial data, audit results, or detailed audit reports. It is not a full audit report or annual report, nor is it a certification or regulatory filing of a different nature. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure announcement that does not fit into more specific categories like Audit Report or Management Information.
2022-09-21 English
ICRA, the credit rating agency has downgraded the long-term rating on the Rs. 176 crs bank facilities of the Company to [ICRA] A- (Stable) (pronounced ICRA A minus with a Stable outlook). ....
Capital/Financing Update Classification · 95% confidence The document is an official communication from Unichem Laboratories Limited to stock exchanges regarding a credit rating downgrade by ICRA for the company's bank facilities. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content includes the rating downgrade details, the rating agency's letter, and annexure with bank limits and ratings. There are no financial statements or detailed financial performance data presented. The document is an announcement of a credit rating update, which is a capital/financing related update rather than a full financial report or audit. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the rating change, not just a brief notice or report publication announcement.
2022-09-19 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is an official communication from Unichem Laboratories Limited to stock exchanges regarding a credit rating downgrade by ICRA for the company's bank facilities. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is primarily an announcement of a credit rating change, including the rating agency's letter and details of the rating downgrade. There are no financial statements or detailed financial performance data presented. The document is a regulatory announcement about a credit rating update, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-09-19 English
Press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Carbamazepine Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release dated August 23, 2022, announcing the receipt of ANDA approval from the USFDA for a pharmaceutical product. It is addressed to stock exchanges under SEBI regulations, indicating it is a regulatory announcement. The content focuses on the approval and marketing plans for a drug, with no financial statements, detailed financial performance, or management discussion. The document length is 3397 characters, which is relatively short and typical for a press release or regulatory announcement rather than a full report. There is no indication of it being an earnings release, annual report, or other detailed financial filing. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about a material event (FDA approval) but not a financial report or detailed investor presentation.
2022-08-23 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a press release dated August 23, 2022, announcing that Unichem Laboratories Limited has received ANDA approval from the USFDA for a generic drug. It is an update about a regulatory approval and product commercialization, not a financial report, earnings release, or management discussion. The document is short (3397 characters) and serves as an announcement rather than a detailed report. It does not contain financial statements or detailed financial data. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to regulatory approval impacting the company's product portfolio and potential market expansion, which is a form of business update relevant to capital and financing activities.
2022-08-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.